NICE Endorses Dupilumab for Eosinophilic COPD T...

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance re...
Accelerating FAST-EU Clinical Trials
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
Navigating Economic Resilience Through Life Sciences Investment
Guiding Principles for Ethical AI Integration in Drug Development
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...